Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000

A t(8;21) is the most frequent abnormality in AML in children. Patients with this genetic abnormality are traditionally expected favorable prognosis with a probability of cure up to 80 %. Known additional cytogenetic abnormalities in AML with t(8;21) not affecting prognosis. These include loss of on...

Full description

Bibliographic Details
Main Authors: I. I. Kalinina, M. M. Shneyder, N. P. Kirsanova, D. D. Baydildina, E. V. Suntsova, O. V. Goronkova, L. A. Khachatryan, G. A. Novichkova, M. A. Maschan, R. I. Yutskevich, E. V. Volochnik, T. V. Savitskaya, N. V. Minakovskaya, I. V. Proleskovskaya, I. V. Emelyanova, O. V. Karas, N. V. Migal, Yu. E. Mareyko, A. G. Drekov, J. V. Rumyantseva, E. V. Fleyshman, T. V. Nasedkina, O. V. Aleynikova, A. A. Maschan
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/100
_version_ 1797855561857892352
author I. I. Kalinina
M. M. Shneyder
N. P. Kirsanova
D. D. Baydildina
E. V. Suntsova
O. V. Goronkova
L. A. Khachatryan
G. A. Novichkova
M. A. Maschan
R. I. Yutskevich
E. V. Volochnik
T. V. Savitskaya
N. V. Minakovskaya
I. V. Proleskovskaya
I. V. Emelyanova
O. V. Karas
N. V. Migal
Yu. E. Mareyko
A. G. Drekov
J. V. Rumyantseva
E. V. Fleyshman
T. V. Nasedkina
O. V. Aleynikova
A. A. Maschan
author_facet I. I. Kalinina
M. M. Shneyder
N. P. Kirsanova
D. D. Baydildina
E. V. Suntsova
O. V. Goronkova
L. A. Khachatryan
G. A. Novichkova
M. A. Maschan
R. I. Yutskevich
E. V. Volochnik
T. V. Savitskaya
N. V. Minakovskaya
I. V. Proleskovskaya
I. V. Emelyanova
O. V. Karas
N. V. Migal
Yu. E. Mareyko
A. G. Drekov
J. V. Rumyantseva
E. V. Fleyshman
T. V. Nasedkina
O. V. Aleynikova
A. A. Maschan
author_sort I. I. Kalinina
collection DOAJ
description A t(8;21) is the most frequent abnormality in AML in children. Patients with this genetic abnormality are traditionally expected favorable prognosis with a probability of cure up to 80 %. Known additional cytogenetic abnormalities in AML with t(8;21) not affecting prognosis. These include loss of one sex chromosome and del(9q-). Prognosis impact of additional abnormalities involving chromosomes 7 and 11 in patients with t(8;21) is unknown. The purpose of this study was to analyse of additional anomalies, that occur in patients with t(8;21), and their influence on prognosis. During the study period 173 children with AML have received AML-MM-2000 treatment protocol in Russia and Belarus. Of these, in 33 patients (11 girls and 22 boys, median age — 10.5 years) t(8;21) was detected by chromosome banding or molecular-genetic analysis. In group with t(8;21) CNS leukemia in 8 patients was detected, extramedullary lesion — in 8 patients. In 4 patients CNS leukemia combined with presence of extramedullary lesions. These factors did not influence on therapy outcome. Overall survival of AML patients with t(8;21) was 0,67 ± 0,08 compared to 0,44 ± 0,04 in patients with AML without this translocation (p = 0,04). Special subgroup consist of 5 patients with t(8;21) and identified chromosomal abnormalities affecting chromosome 7 and 11, which were a poor prognostic factor: event-free survival in this subgroup of patients (n = 5) was 0,0 ± 0,0, compared to 0,34 ± 0,16 in patients with t(8;21) without additional anomalies (n = 28) (p = 0,027).
first_indexed 2024-04-09T20:25:48Z
format Article
id doaj.art-bf667c92bc8e402b98a4f672d0a72303
institution Directory Open Access Journal
issn 1818-8346
2413-4023
language Russian
last_indexed 2024-04-09T20:25:48Z
publishDate 2014-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj.art-bf667c92bc8e402b98a4f672d0a723032023-03-30T20:15:10ZrusABV-pressОнкогематология1818-83462413-40232014-07-0161111910.17650/1818-8346-2011-6-1-11-19115Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000I. I. Kalinina0M. M. Shneyder1N. P. Kirsanova2D. D. Baydildina3E. V. Suntsova4O. V. Goronkova5L. A. Khachatryan6G. A. Novichkova7M. A. Maschan8R. I. Yutskevich9E. V. Volochnik10T. V. Savitskaya11N. V. Minakovskaya12I. V. Proleskovskaya13I. V. Emelyanova14O. V. Karas15N. V. Migal16Yu. E. Mareyko17A. G. Drekov18J. V. Rumyantseva19E. V. Fleyshman20T. V. Nasedkina21O. V. Aleynikova22A. A. Maschan23Federal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyRepublic Center of Pediatric Oncology and HematologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyRepublic Center of Pediatric Oncology and HematologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyInstitute of Cancerogenesis, N.N. Blokhin Cancer Research Center, Russian Academy of Medical SciencesEngelhardt Institute of Molecular Biology, Russian Academy of SciencesRepublic Center of Pediatric Oncology and HematologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyA t(8;21) is the most frequent abnormality in AML in children. Patients with this genetic abnormality are traditionally expected favorable prognosis with a probability of cure up to 80 %. Known additional cytogenetic abnormalities in AML with t(8;21) not affecting prognosis. These include loss of one sex chromosome and del(9q-). Prognosis impact of additional abnormalities involving chromosomes 7 and 11 in patients with t(8;21) is unknown. The purpose of this study was to analyse of additional anomalies, that occur in patients with t(8;21), and their influence on prognosis. During the study period 173 children with AML have received AML-MM-2000 treatment protocol in Russia and Belarus. Of these, in 33 patients (11 girls and 22 boys, median age — 10.5 years) t(8;21) was detected by chromosome banding or molecular-genetic analysis. In group with t(8;21) CNS leukemia in 8 patients was detected, extramedullary lesion — in 8 patients. In 4 patients CNS leukemia combined with presence of extramedullary lesions. These factors did not influence on therapy outcome. Overall survival of AML patients with t(8;21) was 0,67 ± 0,08 compared to 0,44 ± 0,04 in patients with AML without this translocation (p = 0,04). Special subgroup consist of 5 patients with t(8;21) and identified chromosomal abnormalities affecting chromosome 7 and 11, which were a poor prognostic factor: event-free survival in this subgroup of patients (n = 5) was 0,0 ± 0,0, compared to 0,34 ± 0,16 in patients with t(8;21) without additional anomalies (n = 28) (p = 0,027).https://oncohematology.abvpress.ru/ongm/article/view/100childrenacute myeloid leukemiat(821)aml-mm-2000 protocol
spellingShingle I. I. Kalinina
M. M. Shneyder
N. P. Kirsanova
D. D. Baydildina
E. V. Suntsova
O. V. Goronkova
L. A. Khachatryan
G. A. Novichkova
M. A. Maschan
R. I. Yutskevich
E. V. Volochnik
T. V. Savitskaya
N. V. Minakovskaya
I. V. Proleskovskaya
I. V. Emelyanova
O. V. Karas
N. V. Migal
Yu. E. Mareyko
A. G. Drekov
J. V. Rumyantseva
E. V. Fleyshman
T. V. Nasedkina
O. V. Aleynikova
A. A. Maschan
Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
Онкогематология
children
acute myeloid leukemia
t(8
21)
aml-mm-2000 protocol
title Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
title_full Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
title_fullStr Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
title_full_unstemmed Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
title_short Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
title_sort clinical and genetic characteristics of acute myeloid leukemia with t 8 21 in children and results of therapy according to protocol aml mm 2000
topic children
acute myeloid leukemia
t(8
21)
aml-mm-2000 protocol
url https://oncohematology.abvpress.ru/ongm/article/view/100
work_keys_str_mv AT iikalinina clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT mmshneyder clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT npkirsanova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ddbaydildina clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT evsuntsova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ovgoronkova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT lakhachatryan clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ganovichkova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT mamaschan clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT riyutskevich clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT evvolochnik clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT tvsavitskaya clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT nvminakovskaya clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ivproleskovskaya clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ivemelyanova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ovkaras clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT nvmigal clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT yuemareyko clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT agdrekov clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT jvrumyantseva clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT evfleyshman clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT tvnasedkina clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT ovaleynikova clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000
AT aamaschan clinicalandgeneticcharacteristicsofacutemyeloidleukemiawitht821inchildrenandresultsoftherapyaccordingtoprotocolamlmm2000